Extrait

The primary objective of the trial is to evaluate the efficacy response to nivolumab monotherapy in cohorts of patients with unresectable locally advanced or metastatic, non-clear cell RCC, rare head and neck cancer, rare skin cancer, MSI-nonCRC or penile cancer, which is resistant or refractory to standard therapy, and for which no other treatment options are available.

Critère d'inclusion

• Unresectable locally advanced or metastatic, non-clear cell renal cell carcinoma, rare head and neck cancer, rare skin cancer, MSI-nonCRC or penile cancer, which is resistant or refractory to standard therapy, or for which standard therapy does not exist, or is not considered appropriate, and for which no other experimental treatment options are available

Liens

• euctr